Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Key Information
Due Date: November 5, 2024
Agency: U.S. Department of Health and Human Services (HHS)
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: Not Specified
Funding Type: Cooperative Agreement, Philanthropy
Match Required: No
Contact Info:
OERWebmaster03@od.nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
The Alzheimer's Drug-Development Program is offering a grant opportunity, with applicants able to pursue clinical trials if they wish. This funding is aimed at supporting work in the early stages of clinical development (Phase I), which includes the pre-clinical stage, of new medications. The proposed medications should be either biologic or small molecule in nature. The goal for these potential drugs is to prevent Alzheimer's disease, slow down its progression, or treat the cognitive and behavioral symptoms of the disease.
Show More
Key Dates
Open Date: November 15, 2021
Application Due Date: November 5, 2024
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses